Regulus Therapeutics

#6764

Rank

$564.95M

Marketcap

United States

Country

Leadership team

Mr. Joseph P. Hagan M.B.A. (Pres, CEO & Director)

Ms. Crispina Calsada CPA (Chief Financial Officer)

Mr. Christopher Ray Aker J.D. (Sr. VP, Gen. Counsel & Corp. Sec.)

Products/ Services

Biotechnology, Genetics, Health Care, Therapeutics

Headquarters

San Diego, California, United States

Established

2007

Company Registration

SEC CIK number: 0001505512

Traded as

RGLS

Social Media

URL

https://www.regulusrx.com

Overview

Location

Recognition and Award

References

Summary

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

History

Regulus was founded in 2007 by Alnylam Pharmaceuticals, Isis Pharmaceuticals and the Cystic Fibrosis Foundation to create novel medicines targeting microRNAs, which are recently discovered molecules, widely distributed in cells, that regulate gene expression and play a critical role in disease pathways.

Mission

At Regulus, our mission is to discover, develop and commercialize innovative medicines targeting microRNAs to address significant unmet medical needs.

Vision

Our vision is to be the premier small molecule-based research organization in the rapidly emerging field of microRNA-based therapeutics.

Key Team

Mr. Daniel J. Penksa (Sr. Director of Fin. & Controller)

Mr. Firuz Shakoori (Head of CMC)

Dr. Claire Susan Padgett M.S., M.T., Ph.D. (Sr. VP of Clinical Operations)

Dr. Rekha Garg M.D., M.S. (Sr. VP of Clinical Devel. & Regulatory)

Recognition and Awards

Regulus has received awards, including the 2008 Leading Edge Award for Biotechnology from the Cystic Fibrosis Foundation and the 2013 Prix Galien USA Research Award for Best Biotechnology Product.